Does Pfizer Inc. (PFE)’s Unwinding of Its Stake in Zoetis Inc (ZTS) Offer Value for Either Company’s Shareholders?

Page 1 of 2

Pfizer Inc. (NYSE:PFEsurprised the investment community with the recent announcement that it would attempt to offload the remainder of its stake in veterinary pharmaceutical firm Zoetis Inc (NYSE:ZTS). At minimum, the transaction would be designed to reduce Pfizer’s take in Zoetis to non-majority, non-controlling levels. However, the ultimate goal appears to be the complete liquidation of Pfizer’s interest in its former subsidiary. Although many industry observers expected that this would eventually occur, many have been surprised by the speed and efficacy with which Pfizer appears to be committed to divorcing itself from Zoetis.

Pfizer Inc. (NYSE:PFE)

This transaction could offer a few key advantages for rank-and-file Pfizer investors. On the other hand, it might temporarily impact the earning power of newly minted Zoetis Inc (NYSE:ZTS) shareholders. However, both of these companies are strong and seem well-prepared to handle temporary volatility. Investors who wish to profit from this special situation should start by comparing Pfizer Inc. (NYSE:PFE), Zoetis and other major drug-makers.

Pfizer, Zoetis and the Competition

Pfizer competes with several major pharmaceutical companies as well as a number of smaller, more narrowly focused outfits. Although it does not enjoy much operational overlap, Zoetis Inc (NYSE:ZTS) also competes with major drug-makers by virtue of its size. One of both firms’ closest competitors is Merck & Co., Inc. (NYSE:MRK) .

Pfizer Inc. (NYSE:PFE) and Merck are far larger than Zoetis. At last count, Pfizer’s market capitalization came in at just over $205 billion. Merck enjoyed a market valuation of around $142 billion. Meanwhile, Zoetis reported a comparatively puny valuation of about $16.7 billion. Despite its enormous size, Pfizer is currently the most profitable of these three firms: At 27%, its profit margin is roughly double that of Merck and (NYSE:MRK) exceeds that of Zoetis by a factor of three. Moreover, Pfizer reported an impressive quarterly earnings growth figure of over 50%. With an earnings increase of 26%, Zoetis also appears to be enjoying some profit momentum. By comparison, Merck recently saw its quarterly earnings shrink by a little over 8 percent.

With just slightly more debt than cash and strongly positive cash flow figures, Pfizer and Merck have similar-looking balance sheets. By comparison, Zoetis Inc (NYSE:ZTS)’s financials look slightly weaker: The company has about $3.7 billion in debt to just $468 million in cash. Fortunately, it has an operating cash flow of around $740 million.

How the Deal Is Structured

According to the terms of the deal, all Pfizer Inc. (NYSE:PFE) shareholders are currently eligible to participate in this secondary offering. The offering will be structured as a one-way share swap. As soon as the program begins, individual Pfizer shareholders will be permitted to exchange their holdings for proportional numbers of Zoetis shares. To increase interest in the offering, Pfizer has indicated that shareholders who participate in the deal will earn a premium of between 7 and 8 percent. Although the exact premium will be based on pre-closing trading averages and will not be announced until June 19, it is currently expected to be near 7.5 percent. In other words, Pfizer shareholders who participate in the swap will receive “extra” Zoetis Inc (NYSE:ZTS) shares valued at 7.5 percent of their previous Pfizer holdings.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 44 percentage points in 21 months Learn how!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!